摘要
突变生物合成作为产生抗生素衍生物的重要手段,自20世纪70年代兴起以来,发挥了巨大作用,已开发出许多至今在临床上仍广泛使用的抗生素品种。随着基因技术的发展,突变生物合成技术可直接对次级代谢途径中一特定酶基因进行改造获得突变株,大大提高了工作效率和准确性。本文综述了突变生物合成技术在微生物药物领域的应用,特别是结合基因技术进行突变生物合成研究的新进展。
Mutational biosynthesis since its rising in 1970＇s, as a tool for the formation of antibiotic structural analogues, has played an important role and developed some novel derivatives which are still widely used in the clinic today. With the advance of gene engineering, mutants can be obtained by direct gene modification to certain enzyme in secondary metabolism pathway and efficiency is greatly promoted. In this paper, the progress, especially combining gene engineering of mutational biosynthesis is reviewed.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2007年第2期65-72,94,共9页
Chinese Journal of Antibiotics
关键词
突变生物合成
突变合成元
阻断突变株
抗生素
Mutational biosynthesis （MBS）
Mutasynthon
Blocked mutant
Antibiotics
